Real-World Efficacy of COVID-19 Pre-Exposure Prophylaxis with Tixagevimab/Cilgavimab in People with Multiple Sclerosis

• Published in: Vaccines (Basel) Vol. 11; no. 12; p. 1855
• Main Authors: Elias, Luke B, Jaber, Aliya, Manzano, Margarita, Leekoff, Mark, Sylvester, Andrew, Tremblay, Matthew A
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.12.2023; MDPI
• Subjects: Antibodies; Brand names; Brief Report; cilgavimab; Consent; COVID-19; COVID-19 vaccines; Disease prevention; Dosage and administration; Drug therapy; Drug therapy, Combination; Effectiveness; Infections; Monoclonal antibodies; Morbidity; Multiple sclerosis; Omicron; Patient outcomes; Prophylaxis; Reduction; Regression analysis; Severe acute respiratory syndrome coronavirus 2; tixagevimab; Viral diseases; United States; United States > US; COVID-19; Omicron; cilgavimab; multiple sclerosis; tixagevimab

Vaccines against the SARS-CoV-2 virus were authorized for use by the Food and Drug Administration (FDA) in the United States and have proven effective for the prevention of morbidity and death from COVID-19. Certain immunosuppressant medications prevent the development of protective immunity followi...